Breast Cancer is the leading cause of cancer in women. It is well-established that early diagnosis is very critical in saving a life of a cancer patient. Co-founded by Geetha Manjunath and Nidhi Mathur, researchers at NIRAMAI have developed a new cancer screening software that uses machine intelligence over thermography images to enable a low cost, easy to use, portable solution and requires minimal human supervision. NIRAMAI solution uses a high resolution thermal sensing device and cloud hosted analytics solution for analysing the thermal images. The SaaS solution uses big data analytics, artificial intelligence and machine learning for reliable, early and accurate breast cancer screening. The innovative methods used in the solution have led to multiple US patents.
Imagine a world where music, movies, and art are seamlessly created by AI - where AI generates music that is a mashup of Ed Sheeran and Mozart, or any of your favorite artists, instantaneously upon a mouseclick. Tools to create all forms of content, in real-time, would be available to creators who would just provide basic inputs on genre, moods, themes, and styles. A digital artist would be able to animate their work and add a fitting soundtrack to it, without any human oversight. This world isn’t very far away. Our research at pi Ventures shows that very soon, AI will be able to generate content synthetically across various use cases, taking care of the artists’ operational workload - yes, we believe that ‘Synthetic Content Creation’ will go from casual usage today to professional adoption over the next 3 to 5 years. Similarly, we have delved into 15 upcoming themes and how they will shape the world, and what disruptive technology shifts are expected to take place in the next 5 years as part of our DeepTech Shifts 2026 report. The report is based on our research and insights after discussions with over 4,000 entrepreneurs across the world and covers various technologies that we believe will reach an inflection point by 2026. We are extremely excited to present this to you and hope that you enjoy reading it. Please click the button below to read the report:
Diverse and Global experience across Technology & Investments
Our core team brings decades of operating experience in building disruptive technology companies, business strategy, and global investments. While we bring diverse perspectives, we are bound by a shared passion for backing bold entrepreneurs in DeepTech. We believe in conviction-led investing and supporting our founders throughout their journey.
Fund II will look at companies focused on disruptive AI and other forms of Deep Tech across sectors including but not limited to Blockchain, Spacetech, Biotech, Material Science, etc. Through a corpus that is 3x as large as Fund I, we will aim to go deeper in portfolio winners in subsequent rounds.
immunitoAI is developing an AI-powered platform for antibody discovery and screening. The platform screens and ranks the best antibody candidates for a given target/antigen. With this technology, the discovery process can be made 2x more efficient while improving the success rate.